BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31754769)

  • 1. Intraoperative detection of isocitrate dehydrogenase mutations in human gliomas using a miniature mass spectrometer.
    Brown HM; Pu F; Dey M; Miller J; Shah MV; Shapiro SA; Ouyang Z; Cohen-Gadol AA; Cooks RG
    Anal Bioanal Chem; 2019 Dec; 411(30):7929-7933. PubMed ID: 31754769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
    Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
    J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer.
    Pu F; Alfaro CM; Pirro V; Xie Z; Ouyang Z; Cooks RG
    Anal Bioanal Chem; 2019 Mar; 411(8):1503-1508. PubMed ID: 30710208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry.
    Hua W; Zhang W; Brown H; Wu J; Fang X; Shahi M; Chen R; Zhang H; Jiao B; Wang N; Xu H; Fu M; Wang X; Zhang J; Zhang X; Wang Q; Zhu W; Ye D; Garcia DM; Chaichana K; Cooks RG; Ouyang Z; Mao Y; Quinones-Hinojosa A
    Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2318843121. PubMed ID: 38805277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration.
    Brown HM; Alfaro CM; Pirro V; Dey M; Hattab EM; Cohen-Gadol AA; Cooks RG
    J Appl Lab Med; 2021 Jul; 6(4):902-916. PubMed ID: 33523209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry.
    Kanamori M; Maekawa M; Shibahara I; Saito R; Chonan M; Shimada M; Sonoda Y; Kumabe T; Watanabe M; Mano N; Tominaga T
    Brain Tumor Pathol; 2018 Apr; 35(2):90-96. PubMed ID: 29671246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue 2-Hydroxyglutarate as a Biomarker for
    Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX
    Clin Cancer Res; 2019 Jun; 25(11):3366-3373. PubMed ID: 30777876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
    Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
    J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
    Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
    Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
    Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
    Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower Lactate Levels and Lower Intracellular pH in Patients with
    Wenger KJ; Steinbach JP; Bähr O; Pilatus U; Hattingen E
    AJNR Am J Neuroradiol; 2020 Aug; 41(8):1414-1422. PubMed ID: 32646946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.